Symbicort SMART (Symbicort Maintenance And Reliever Therapy)

This study has been completed.

First Received on August 29, 2007. Last Updated on July 10, 2009 History of Changes

Sponsor:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00523679

Purpose

The purpose of this study is to investigate the extent of Symbicort use in patients prescribed Symbicort as maintenance and reliever therapy.

Condition
Asthma

Study Type:	Observational
Study Design:	Observational Model: Case-Only Time Perspective: Prospective
Official Title:	SMART (Symbicort Maintenance And Reliever Therapy): Reassure Program for Patients Using Symbicort Turbuhaler as Maintenance and Reliever Therapy in Korean Clinical Practice

Resource links provided by NLM:

MedlinePlus related topics: Asthma

Drug Information available for: Symbicort

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Estimated Enrollment:	2000
Study Start Date:	July 2007
Study Completion Date:	July 2008

Eligibility

Ages Eligible for Study:	12 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

Hospital Outpatient Clinics

Criteria

Inclusion Criteria:

Asthma patients prescribed Symbicort as maintenance and reliever therapy, according to the label, before inclusion in this program.

Exclusion Criteria:

Since this programme intends to describe Symbicort use in routine clinical practice when prescribed as Symbicort maintenance and reliever therapy, there are no programme specific exclusion criteria, other than: involvement in the planning and conduct of the programme (applies to both AstraZeneca staff or staff at the investigational site)

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00523679

Locations

Korea, Republic of
Research Site
Seoul, Jongro-gu, Korea, Republic of
Research Site
Seoul, Kangnam-gu, Korea, Republic of
Research Site
Seoul, Songpa-gu, Korea, Republic of

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:

Joon-Woo Bahn

AstraZeneca Korea

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00523679 History of Changes
Other Study ID Numbers:	NIS-RKR-SYM-2007/1
Study First Received:	August 29, 2007
Last Updated:	July 10, 2009
Health Authority:	South Korea: Korea Food and Drug Administration (KFDA)

Keywords provided by AstraZeneca:

Asthma
Symbicort
SMART
inhaler

compliance
Naturalistic
Observational

Additional relevant MeSH terms:

Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate

Hypersensitivity
Immune System Diseases
Symbicort
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on February 09, 2012